NTEC Trying ....AGAINNTEC trying to break and hold above this 786 fib level ....AGAIN. It was a previous area of support leading up to the last sell-off but since breaking below it has remained a sticky level of resistance.
"Aside from the cannabis directive, the company has also built a stronger pipeline for things like cancer. In fact, late last month, a patent abstract from Decoy surfaced. It showed that this was for Decoy’s “Compositions and methods for treatment of cancer using bacteria’ and that the patent was granted. With the latest proposed merger seemingly coming to fruition, this additional piece could give the company more exposure to the mounting cancer trend in the market recently. Shares have catapulted to highs of $17.80 during the week."
Read More about this Decoy/Intec Deal: 3 Biotech Penny Stocks To Watch On Robinhood IPO Day
Stockstowatch
ABIO Caught Between Two FibsOn this episode of "Between Two Fibs" ABIO once again tested the 618 line plotted after using the recent low as the anchor. This has been a failure point 2 other times in the last few weeks but with a little more afternoon momentum, it will be interesting to see if it can break and hold above it. Other than that, the 786 fib appeared to have acted as lower support a few times prior to gapping down recently. With today's big swing, that could be another key level for ABIO to hold at or above.
See More: 3 Biotech Penny Stocks To Watch On Robinhood IPO Day
AMZN Charts Lower Peak on Daily Ahead of QuarteliesThe above chart shows the daily time frame for AMZN. Price action has charted a lower peak ahead of the company’s quarterly release. It seems it's at a tipping point in the short term. If price continues lower along the broken red line trajectory a lower trough will chart. This will put the company into a downtrend on the daily. The second possibility is that price locks in a higher trough near current levels and then moves higher along the broken green line trajectory. This will result in a higher trough followed by a higher peak, which is defined uptrend on the daily. Forward guidance will play a role here (we have already seen FB indicate a likely slowdown of revenue during the second half, which has alarmed)
Spotify (SPOT) Stock. A Lot Of Buy Signals On D1.Spotify (SPOT),D1: Support level + Bollinger bands + Hammer + Volume + Oversold + Discout
FXCM's US.ECOMM Basket Dips on Hourly But Daily Bullish PositionFXCM's US ECOMM Basket is made up of ETSY, W, SHOP, WMT, EBAY, and AMZN. Its daily price is in the bullish area on the left. The hourly stochastic has crossed bullishly but the EMAs are yet to trigger upwards. If they do, it potentially signals that short-term traders have aligned themselves with the daily timeframe. A movement of stochastic to the 80 level and maintenance of that level (blue arrow) increases the chance of a successful trade. Trend following indicators may be useful in this case as a potential exit tool. Stop under hourly support in conjunction with risk management techniques.
FXCM's BioTech Basket Short-Term Pullback in Daily StrengthFXCM's BIOTECH basket is in the bullish area on the daily chart on the left. The basket is made up of equal weighting of 2% each in ABBV, AMGN, GILD, CELG and VRTX. A bullish cross of EMAs and stochastic potentially align short-term traders with the daily. If signals occur, movement of stochastic to 80 level and maintenance of that level increase chance of a successful trade in terms of 4 point pattern (red 1234). Trend following indicators may be useful in this case as a potential exit tool. Stop under hourly support in conjunction with risk management techniques.
IMV back at key technical levelIMV surged during late trading on 7/23 with post market action taking it to highs of $3 and ultimately settling back around $2.65. There are a few areas to follow that appeared on the chart after plotting some fibs and looking for s/r areas. First, the aftermarket price lines up with a very consistent level of support/resistance between last May and present day. You've also got the 200DMA, which sat around $3 on Friday and clearly was a level that put the brakes on that late session rally. Both areas will be interesting to watch at the top of the week. Further, IF it can make it through both levels , you've got the 618 & 50 fib line levels to keep an eye on. In both cases, they've aced as some s/r levels in the past few months. Fundamentally, we've also got some filings to keep in mind (pennystocks.com).
Next Levels For NRXPFollowing up with the NRXP levels from earlier this month, it looks like before it reaches the 618 fib line, there's a pretty clear area of high traffic that has acted as both support and resistance over the last few months. That happens to sit right around the $28-$30 area. Aftermarket on Friday, NRXP failed to hold above it and settled back down just shy of $27. With 2 big volume days on the front end of this move, it will be interesting to see if this same area will act as resistance or if NRXP can firmly push back above it to possibly test the 618 fib level. Also, the 200DMA may be an interesting technical trend line to follow to see if it ultimately acts as a new support for the stock.
"According to the company, 'In the recently-completed phase 2b/3 trial, patients treated with placebo experienced a statistically significant elevation in interleukin 6 (IL-6) cytokine levels, whereas those treated with ZYESAMI™ had a minimal increase in IL-6. Change in cytokine level was a prespecified endpoint of the study.'...The data were submitted to the FDA as a supplement to its pending Emergency Use Authorization application. The company has also planned on submitting a biomarker letter of intent to the FDA. NRX has explained that cytokine release syndrome or “cytokine storm” has been related to mortality in a number of conditions including Acute Respiratory Distress Syndrome. Since these data also have to do with a pending EUA application for ZYESAMI, Wednesday’s further details may be something to keep mindful of heading into the week."
Quote Source: Small-Cap Stocks To Watch After CYTK Sheds Spotlight On Biotech
NAOV Levels For MondayTaking a look at NAOV trading activity on Friday shows post-market action took the stock back up toward the 236 fib line from a retracement using 2019's highs of around 4.50. NAOV hit 3.61 around 6PM ET then got slammed lower, back down below the 382 fib line by the final bell. since that sits right around $3 that could be an important level to monitor if you're looking at NAOV heading into the week. This Fib level was also a previous area of resistance in Late 2019 and early 2021.
Something else to keep in mind is the upcoming proxy vote where the company will look to increase its authorized share count to 40 million. Either way, after such a huge parabolic move, it's going to be important to watch premarket action to see if NAOV can hold these levels at the start of the week.
NVDA Earnings PlayNVDA looks like its about ready to launch to test ATH at 208.75
once we break that level i see 227.04 as the first level i would take profits as that would complete wave 5.
i would watch carefully at this point ti see If price breaks 227.04 with strong volume... if it does and things look good, i would enter calls again and ride to 253.87.
Enjoy my thoughts!
XBIO Parabolic Or New Massive Bull Trend?XBIO stock surged on its highest volume in months for no apparent reason. No news, no filings, and the most recent was the departure of Dr. Genkin from the Board. Obviously, the focus on low float penny stocks has been apparent in the stock market this week. XBIO could be the next iteration of that trend. So let's take a look at some levels. I plotted the fib retracement using November's low as the anchor and the current high from December and the upper limit. Wouldn't you know it, look at the levels and what they show. Not only is that 236 area a key level that XBIO failed at before, BUT the 382 and 50 have posed significant levels of importance too. First, the 382 is where XBIO was ultimately tested by EOD on the big day in December. But then it completely fell apart after it announced that offering. Now look at the 50 fib. This seems to have been a more consistent level of resistance over the last 7 months. XBIO failed to break and hold above it in February and then came within striking distance of testing it earlier this month. Now that it has firmly broke through these two levels, we see it tested the 236 fib and failed in the morning. In light of recent bullishness and volume, this could be an interesting level to keep track of for longs.
" In its latest financial report for Q1 2021, the company posted a net loss of $1.3 million alongside a $10 million cash balance. And while it does have a promising pipeline of proprietary products, it is difficult to say for certain why shares of XBIO stock shot up so heavily today. Regardless, it’s up to you to decide if XBIO stock is worth watching. "
Quote Source: 3 Penny Stocks That Exploded Today, One Up 144%
IPA Fibbing Right Now Needs 786 Hold?IPA is the latest retail banger this week after NURO and CEMI took center stage during the first half. I took out the fibs back to the previous lows and plotted against the ATH. Interesting levels formed which showed pivot support/resistance at the 786 fib line and the 618 maintaining a secondary level of importance. After failing to break and hold above it, longs may be looking to see this 786 fib level to hold as a new support. This move was on COVID news with "potential" in the headline. So take that FWIW. Also have the upcoming corporate call next week on the 28th.
" Over the last few days alone, we’ve seen seriously bullish action in the stock market. Today former penny stock ImmunoPrecise (NASDAQ:IPA) was the latest to grab attention from retail traders. On Monday (7/19), IPA stock was traded around $5 with a volume of fewer than 60,000 shares. Fast-forward to today (7/22), and IPA stock reached highs of $16.47 before the afternoon session got into full swing, with more than 60 million shares traded...This wasn’t an outlier either. Other stocks this week like Chembio Diagnostics, Inc. (NASDAQ:CEMI) and NeuroMetrix Inc. (NASDAQ:NURO) made parabolic moves as well. CEMI stock jumped from lows of $2.20 to highs of $6.95, while NURO stock jumped from around $3 on Monday to over $40 today. "
Quote Source: 7 Penny Stocks To Buy According To Analysts With Targets Up To 316%
SIEMENS - Perfect set up for a swing trade Satisfies the 2 BB strategy.
Keep Stop loss as last swing low.
Reversal of polarity found in daily TF.
CEMI Levels & Things To Consider NextCEMI made a heck of a run on 7/21 so I figured we should do a quick and dirty Fib Retracement. Using the most recent low as the anchor and the high from JUST before CEMI gapped down last June, the candles line up with some interesting levels. It looks like the 786 fib line has consistently held as major support before breaking down below it this last time around. One of the more consistent levels of resistance seems to have been around that 50 fib line. Whenever CEMI approached it or briefly tested it, it wasn't able to sustain price much longer if at all. Now that it has gone ap sh*t, there's a few things to keep in mind both technical and fundamental. First, technical, CEMI has broken firmly above the 50 fib so this would theoretically be a level to watch to confirm whether it becomes a new support or if it once again acts as resistance. Second, the next level, 236 fib, has only been a "major" resistance point 1 time, so whether that makes it "another level to watch" is to be seen but just in case, it could be another level to watch...
Now, after this move, I'm sure everyone is hyped BUT don't forget what was filed just 2 days ago...
" But…and there’s a but here…keep the company’s filings in mind. Big moves are great, but when companies raise capital, it can put a damper on things depending on the price that the money is raised at. A few days ago, the company filed for an at-the-market offering for up to $60 million. No pricing was disclosed in that 8-K filing . So no matter what analysts are saying, keep this in mind if CEMI is on your list of penny stocks to watch right now. " - Best Penny Stocks To Buy Now? Analysts See 85%-288% Upside In 3
You guessed it...an ATM offering for up to $60 mill. Aside from the technicals, it's important to keep this in mind because if there's an offering at a discount coming from this 8K, who knows what could happen in the market. But...live life one candle at a time I suppose. If CEMI is on your watch list these are all points to keep track of.
Fastly FSLY is bottoming outFastly stock FSLY is bottoming out forming a potential higher low.
The stock could target $53.94 - $57.45 - $60.65 levels consecutively.
NURO Fibbing Right Now Or New Highs Next?I took the NURO chart out to 2019, which was the last time it traded around these levels. After plotting these fibs, wouldn't you know, the 236 and 382 lined up almost EXACTLY with today's action. The 382 could be an important level to watch as this was a prior area of "high traffic" and a support/resistance pivot in 2019. With volume surging, 382 fib line could be a key level t pay attention to.
**The big spike in trading action on July 20th stemmed from FDA news. NeuroMetrix announced that it received FDA Breakthrough Device Designation for treating fibromyalgia. Specifically, its Quell device garnered the interest of the stock market today. The device is non-invasive and is a nerve stimulator covered by 18 U.S. utility patents already. This Breakthrough Device Program aims to help patients gain quicker access to technologies like Quell that could provide more effective treatments.
“We are moving forward with a regulatory filing that could position us to launch Quell for this indication in the second half of next year.”
Shai N. Gozani, M.D., Ph.D., President and CEO of NeuroMetrix
Later this week, the company releases its Q2 results. So if NURO stock is on your list right now, keep July 22nd in mind. The company will also host a conference call before the market opens on that day. Read More On NeuroMetrix .**
Quote Source: 4 Penny Stocks To Watch As Hedge Against Dogecoin Price Drop Today
NVDA going higher. BEAST STOCK!NVDA is splitting 4 to 1 on Tuesday 7/20. With earnings coming up and cheaper share prices after the split, you can bet investors will take this opportunity to grab shares while they are still cheap.
Anyways, Wave 4 bounced right at .382 retracement of wave 3 at 722.97. We also hit the bottom of the upper channel and found solid support there. We will probably get a run into earnings.
I have call options on NVDA
Between Two Fibs - AEMDAEMD seems to like this range between the 786 and 618 fib lines. The 618 has long-been a point of resistance on the chart. Meanwhile, the last few days have seen it test the 786 level but hold both above it AND its 50DMA. No news today but focus on biotechs thanks to CYTK earlier could be a sympathy trigger at play. Also with the Delta varient becoming "a thing," covid stocks in numerous stages of development are becoming more of a focus right now. We'll have to see if 786 fib+ 50DMA post a strong support level and if 618 will remain resistance if or when AEMD takes another swing at it.
50 Fib Level for CREGThis 50 fib level for CREG stock has been a pivot for months. No matter if it's broken out or slid lower, this area remains a magnet for the stock. With higher volume recently and a stronger uptrend on 7/19, 50 fib level is once again a point of interest and an important level to watch. Either way, it's come a long distance since it was on the list of penny stocks to watch .
Something to keep in mind, however, is that the company gained approval for the Authorized Share increase from 10m to 100m ( 7/9/2021 8K filing ). That can sometimes mean they need more wiggle room in their share structure to issue more stock. In line with this, it can also mean dilution depending on the inspiration behind the AH increase. At the very least, it's something to keep in the back of your head if you've got CREG on your watch list right now.
New Highs & Levels For CYTKCYTK put in a fresh high today which was rejected HARD almost immediately after. This came after the company announced positive topline results from 2 cohorts in its REDWOOD-HCM Phase 2 clinical trial of CK-3773274 (CK-274). This is the company’s investigational treatment targeting hypertrophic cardiomyopathy.
“The combined data from Cohorts 1 and 2 in REDWOOD-HCM met our high expectations for this trial of CK-274 in patients with obstructive HCM, given the observed onset of response to initiation of treatment, magnitude and breadth of response, reversibility of LVEF decreases, and favorable tolerability profile,” said Fady I. Malik, M.D., Ph.D., Cytokinetics’ Executive Vice President of Research & Development.
Looks like the 236 fib line - using lows from the major gap down - has been a pivot over the last year or so. CYTK tested that level on July 19th and bounced during the morning session. The big question is can it maintain this as a new support level or is it looking at another breakdown following this huge move?
"Thanks to these results, Cytokinetics expressed its anticipation of what its Phase 3 trial could bring to the table. Let’s put this into perspective. CYTK wasn’t any of the penny stocks that broke out last year. However, its valuation was a fraction of what it is today. Last October, CYTK stock was trading around $15 a share; more than 50% less than its value on July 19th. With that, attention is certainly on smaller biotech stocks right now."
Quote Source: Small-Cap Stocks To Watch After CYTK Sheds Spotlight On Biotech
CRTD Fib RetracementRight now with CRTD the 786 area has presented a relatively frequent area of "traffic" over the last few weeks. The sporadic breakouts show a clear area of resistance on the chart that it hasn't been able to break through. But the fact that it's gotten so heavily rejected puts attention at lower levels imo. Right now, CRTD pre market has show to test the 618 fib line. But after getting denied, the consolidation trend has it back below $4. With this latest bout of momentum it will be interesting to see if it comes back to test the 786 fib again or if it can regain momentum and retest 618 as resistance.
"traders on social media have circulated the stock as one with higher than average short interest. Other than that, there haven’t been any news headlines or filings released in conjunction with the latest market action. Considering that the potential catalyst could be technical in nature, it’s important to understand the dynamics at play. Lower float, higher short interest stocks can be incredibly volatile. While this latest bout of action has put bulls in control, any stall in this trend could see the opposite. So if CRTD stock is on your list right now, keep this in mind."
Quote Source: 4 Hot Penny Stocks To Watch After The 1,100% SGOC Stock Rally
AMC Fibonacci Levels Trend AnalysisThe cat's outta the bag with AMC ...it's a popular stock I guess (joking). But all jokes aside, the apes remain steadfast in their message but it's also time to revisit the technicals. After retracing from lows earlier this year, the Fib levels and current support/resistance areas on the chart seem to be lining up. The 50 Fib line is clearly a pivot that used to appear as a support level that AMC would test but not break below. Now that it has AND after breaking below the 50DMA, you can see that AMC has gotten denied multiple times not only at the 50 fib but also at the 50DMA. The big question for the week is can this fib area see a break and hold above or will the consolidation trend remain intact?
Obviously, apes will be apes and fight to the death but making money is nice too and understanding levels of potential support and resistance are important no matter if you're looking for profit targets or areas of potential buy opportunities. The bigger focus I think may be on what happens at the shareholder vote on the 29th at the AMC annual meeting. There were more details outlined in that proxy statement filed by AMC earlier this month .
MMAT Levels To Watch Right NowNot much happening with major Fib levels for MMAT however, that 200DMA seems to be acting as a potential level of support after falling below the 786 fib line. Meanwhile, there seems to be a level of resistance around $5 that has been the case several times over the last few months. The big question now is will the 200 hold this week?
Also have the SC13 G from last week to keep in mind. Nova Scotia Innovation Corporation (Operating as: Innovacorp) reported a 4.399 % stake in the company. This was an amended 13G and if you look back at the one posted on 7/7, you'll see Innovacorp reported a 6.558 % stake.
